Gentian Diagnostics: First quarter 2026 report

06 May 2026 07:30 CEST

Moss, 6 May 2026

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the first quarter of 2026.

Highlights include:
• Q1 2026 sales amounted to NOK 43.9 million versus NOK 44.5 million in Q1 2025
(-1%), reflecting timing of shipments rather than underlying demand. The organic
growth was 4% in Q1’26 vs Q1’25.

• EBITDA of NOK 5.0 million in Q1 2026 vs NOK 14.0 million in Q1 2025. Profit
before tax of -27.6 million, of which 30.2 million is related to an impairment
of the NT-proBNP development project.

• Gross margin of 53% (64% in Q1’25) influenced by adverse currency developments
and higher raw material prices.

• Overall sales performance was primarily impacted by the timing of a Cystatin C
order worth NOK 5.3 million pushed to subsequent quarters, with no expected
negative impact on full‑year sales.

• Sales of fCAL turbo increased by 10% in Q1 2026 compared to Q1 2025 with solid
performance from existing global partners. Several new accounts added in Q1 in
Europe and in the USA contributing to further growth in 2026.

• Sales to the US were NOK 8.7 million in Q1 2026 vs NOK 3.8 million in Q1 2025
with good Cystatin C performance. The warehouse shift for one of our largest
customers accounts for about NOK 4.5 million of the 2026 revenue.

• Gentian announced a long-term contract renewal with our partner Bühlmann
Laboratories for the fCAL Turbo assay.

• Following a comprehensive review of performance data and market dynamics,
Gentian has decided to discontinue the NT-proBNP development program. This
decision reflects disciplined portfolio prioritisation and enables reallocation
of resources toward higher-return opportunities within the company’s expanding
product pipeline.

Webcast
The company will present the results today at 09.00 am, followed by a Q&A
session. The presentation will be held as a live webcast on the company's
website:

https://www.gentian.com/investor-relation/presentations

The webcast will also be available on the company website after the
presentation.

IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business
controller at Gentian Diagnostics ASA, on 6 May 2026 at 07:30 CET.

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions. Gentian’s expertise and focus lie within
immunoassays, specifically for infections, inflammation, kidney disease and
heart failure. By converting existing and clinically relevant biomarkers to the
most efficient, high-throughput analysers, the company contributes to saving
costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.

More information:
Access the news on Oslo Bors NewsWeb site

672468_GDASA Interim report 1Q 2026.pdf
672468_GDASA Q1 26 presentation.pdf